How much could Vicebio’s $1.15bn acquisition add to Sanofi’s RSV market share by 2030?

Sanofi’s $1.15 billion acquisition of Vicebio Ltd, along with up to $450 million in milestone payments, is being closely watched by investors for its potential to shift the competitive dynamics in the global RSV vaccine market. With Pfizer and Moderna currently dominating with their approved single-pathogen RSV vaccines, Sanofi is betting that Vicebio’s combination vaccine candidates, VXB-241 and VXB-251, can carve out a significant share by targeting broader respiratory protection, especially in older adults.

How big is the RSV market, and what share could Sanofi realistically capture?

The global RSV vaccine market is projected to exceed $10 billion annually by 2030, driven largely by rising adoption in older adults and high-risk populations. Analysts estimate that single-pathogen RSV vaccines, such as Pfizer’s Abrysvo and Moderna’s mRNA-1345, could account for the majority of sales in the near term. However, combination vaccines are expected to gradually gain market share once clinical data supports their broader protection benefits.

Institutional sentiment suggests that if VXB-241 achieves regulatory approval by 2028 or 2029, Sanofi could potentially capture 10–15% of the global RSV vaccine market within its first two years of launch. This projection assumes rapid adoption among healthcare providers prioritizing convenience and broader protection against co-circulating respiratory viruses such as human metapneumovirus (hMPV). Analysts also predict that VXB-251, which adds parainfluenza virus Type 3 (PIV3), could expand Sanofi’s market share further if it becomes the first trivalent respiratory vaccine targeting older adults.

For emerging markets, Sanofi’s molecular clamp-based vaccines are expected to have a stronger impact. Stored at standard refrigeration temperatures (2–8°C), they are easier to distribute than mRNA vaccines requiring ultra-cold storage, positioning Sanofi to dominate in regions where mRNA infrastructure is limited.

Why could combination vaccines drive faster adoption among older adults?

Older adults often face multiple respiratory threats simultaneously, and separate immunizations for each virus are costly and logistically challenging. Sanofi’s combination approach, which integrates RSV and hMPV in VXB-241 and adds PIV3 in VXB-251, addresses this clinical and operational gap. Analysts believe healthcare systems, especially long-term care facilities, will increasingly favor single-shot combination vaccines to simplify immunization schedules and reduce hospitalization rates.

Institutional investors also point out that payers are likely to support combination vaccines if they demonstrate cost-effectiveness by preventing hospitalizations and reducing the need for multiple doses. If Sanofi can produce strong phase 3 data supporting lower hospitalization rates in older adults, its vaccines could become the preferred option for public health programs.

Can Sanofi compete with Pfizer and Moderna’s entrenched market positions?

While Pfizer and Moderna have first-mover advantages, their products are limited to RSV alone. Sanofi’s ability to differentiate with combination vaccines could help it target healthcare providers seeking to streamline older adult vaccination schedules. Analysts argue that by 2030, a significant portion of the RSV market may shift to combination vaccines if their efficacy and safety are proven comparable to single-pathogen alternatives.

However, institutional sentiment remains cautious about Sanofi’s timeline. With VXB-241 still in phase 1 trials and VXB-251 in preclinical development, Sanofi risks entering the market late, allowing Pfizer and Moderna to secure long-term payer contracts. To offset this, Sanofi may need to pursue aggressive pricing strategies or leverage its established influenza vaccine networks to cross-sell combination respiratory immunizations.

What financial impact could this acquisition have on Sanofi’s broader vaccine portfolio?

If Sanofi achieves even a conservative 10% share of the RSV market by 2030, that could translate to $1 billion annually in RSV-related revenues, excluding additional contributions from hMPV and PIV3 components. Analysts believe that if VXB-251 succeeds as a first-to-market trivalent respiratory vaccine, incremental revenues could exceed $1.5 billion annually by the early 2030s.

Institutional investors also see potential for significant operating margin expansion. Unlike mRNA vaccines, which require specialized lipid nanoparticle manufacturing, molecular clamp vaccines can be produced using existing protein-based infrastructure, reducing production costs and improving profitability.

Moreover, integrating these vaccines into Sanofi’s global influenza portfolio could unlock cross-selling opportunities. Analysts predict that bundling combination respiratory vaccines with flu shots could increase adoption in national immunization programs, especially in markets where Sanofi already holds strong influenza vaccine contracts.

What risks could affect Sanofi’s RSV market share ambitions?

Despite its potential, the success of Vicebio’s vaccine candidates hinges on clinical validation. Combination vaccines must demonstrate not only strong immunogenicity but also the absence of antigen interference, a common challenge in multi-pathogen immunizations. Regulatory timelines could also be longer than for single-pathogen vaccines, delaying commercialization.

There is also the risk that Pfizer and Moderna may develop their own combination vaccines before Sanofi completes development, reducing its competitive advantage. Institutional sentiment suggests that Sanofi will need to fast-track trials and potentially pursue strategic partnerships to accelerate time to market.